An Autonomous BMP2 Regulatory Element in Mesenchymal Cells

Boudewijn P.T. Kruithof,¹ David T. Fritz,² Yijun Liu,² Diane E. Garsetti,² David B. Frank,³ Steven K. Pregizer,⁴ Vinciane Gaussin,¹ Douglas P. Mortlock,⁴ and Melissa B. Rogers^{2*}

- ¹Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry (UMDNJ)-New Jersey Medical School (NJMS), Newark, New Jersey
- ²Department of Biochemistry and Molecular Biology, UMDNJ-NJMS, Newark, New Jersey
- ³Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee
- ⁴Department of Molecular Physiology and Biophysics, Center for Human Genetics Research,
- Vanderbilt University School of Medicine, Nashville, Tennessee

ABSTRACT

BMP2 is a morphogen that controls mesenchymal cell differentiation and behavior. For example, BMP2 concentration controls the differentiation of mesenchymal precursors into myocytes, adipocytes, chondrocytes, and osteoblasts. Sequences within the 3'untranslated region (UTR) of the *Bmp2* mRNA mediate a post-transcriptional block of protein synthesis. Interaction of cell and developmental stage-specific transregulatory factors with the 3'UTR is a nimble and versatile mechanism for modulating this potent morphogen in different cell types. We show here, that an ultra-conserved sequence in the 3'UTR functions independently of promoter, coding region, and 3'UTR context in primary and immortalized tissue culture cells and in transgenic mice. Our findings indicate that the ultra-conserved sequence is an autonomously functioning post-transcriptional element that may be used to modulate the level of BMP2 and other proteins while retaining tissue specific regulatory elements. J. Cell. Biochem. 112: 666–674, 2011. © 2010 Wiley-Liss, Inc.

KEY WORDS: GENE REGULATION; POST-TRANSCRIPTIONAL; GROWTH FACTOR; PATHOLOGICAL CALCIFICATION; CORONARY VASCULATURE; AORTA

INTRODUCTION

BMP2 IS A MORPHOGEN THAT CONTROLS CELL DIFFERENTIATION AND BEHAVIOR

BMP2 concentration controls the differentiation of mesenchymal precursors into myocytes, adipocytes, chondrocytes, and osteoblasts [Wang et al., 1993; Katagiri et al., 1994; Denker et al., 1999; Sottile and Seuwen, 2000; Cheng et al., 2003; Rosen and MacDougald, 2006]. In the developing heart, BMP2 levels control cardiac mesoderm commitment and differentiation [Schlange et al., 2000; Schultheiss et al., 1997] and proepicardial identity [Kruithof et al., 2006; Schlueter et al., 2006]. As expected for a morphogen, BMP2

dosage is critical throughout fetal and post-natal development. BMP2-deficient mouse embryos die early in embryogenesis [Zhang and Bradley, 1996]. Conditionally null *Bmp2* alleles have shown that BMP2 is required in the developing heart at later stages and in post-natal bone [Ma et al., 2005; Rivera-Feliciano and Tabin, 2006; Tsuji et al., 2006]. Quantitative aspects of BMP2 function in key structures have been addressed using chimeras with *Bmp2* null embryonic stem cells and wild type blastocysts [Castranio and Mishina, 2009], compound heterozygotes of *Bmp2* and *Bmp4* null alleles [Uchimura et al., 2009], and a hypomorphic allele created by appending a neo cassette to the 3'UTR of the *Bmp2* mRNA [Singh et al., 2008]. Genetic background has been shown to influence the

Grant sponsor: Molecular Resource Facility at the UMDNJ-NJ Medical School; Grant sponsor: Foundation of UMDNJ; Grant sponsor: National Institute of Health; Grant numbers: R01HD31117, R21HL084278, R01HD47880; Grant sponsor: American Heart Association; Grant numbers: 00655881T, 555840T, 0625861T; Grant sponsor: March of Dimes Birth Defects Foundation; Grant number: 1-FY06-375.

Boudewijn P.T. Kruithof's present address is Division of Cardiology, Department of Medicine, Weill Cornell Medical College, New York, NY.

Vinciane Gaussin's present address is WELBIO, LIEGE, Belgium.

*Correspondence to: Melissa B. Rogers, Biochemistry & Molecular Biology (MSB E627), UMDNJ-NJMS, 185 South Orange Ave., P.O. Box 1709, Newark, NJ 07101-1709. E-mail: rogersmb@umdnj.edu

Received 1 September 2010; Accepted 16 November 2010 • DOI 10.1002/jcb.22975 • © 2010 Wiley-Liss, Inc. Published online 6 December 2010 in Wiley Online Library (wileyonlinelibrary.com).

666

severity of defects resulting from BMP2 deficiency, most likely due to differences in *cis* and *trans* regulatory mechanisms that modulate BMP2 synthesis and to differences in downstream signaling [Castranio and Mishina, 2009; Uchimura et al., 2009]. Understanding the regulatory motifs that control the precise level of BMP2 is required to fully understand the diverse roles of this morphogen during embryogenesis.

Aberrant BMP2 levels and function also have been directly implicated in all forms of pathological calcification: atherosclerotic lesions, calcified cardiac valves, and calcified medial arteries [Bostrom et al., 1993; Mohler et al., 2001; Shao et al., 2005; Caira et al., 2006]. The abnormal signaling leading to calcification has been characterized as a reawakening of embryonic signaling paths [Lincoln et al., 2006; Srivastava, 2006] or as ectopic osteogenesis [Vattikuti and Towler, 2004; Hruska et al., 2005; Shao et al., 2006]. Procalcification conditions and signals such as high fat diet, metabolic changes associated with diabetes and other disorders, oxidative stress, mechanical stresses, and tumor necrosis factor $(TNF)\alpha$, induce *BMP2* gene expression in diverse models of vascular disease [Cheng et al., 2003; Cola et al., 2004; Csiszar et al., 2005, 2006; Nett et al., 2006; Shao et al., 2006; Al-Aly et al., 2007]. Pathologically elevated BMP2 levels have been observed both in endothelial [Csiszar et al., 2005, 2006] and mesenchymal vascular cell types [Towler et al., 1998; Cheng et al., 2003; Shao et al., 2006]. Elucidating the roles of BMP2 in diseases including arthritis, cancer, and pathological calcification requires characterizing the mechanisms that modulate BMP2 levels in mesenchymal cells.

HUMAN BMP2 GENE VARIATION

The importance of sequence polymorphisms in controlling human morphological variation and the onset and progression of disease is profound. Not surprisingly, studies have begun to link variation in the *BMP2* gene and its regulatory elements to various human conditions: genetic hemochromatosis [Milet et al., 2007, 2010], bone quality and osteoporosis [Styrkarsdottir et al., 2003; Reneland et al., 2005; Choi et al., 2006; McGuigan et al., 2007; Tranah et al., 2008], osteoarthritis [Valdes et al., 2004, 2006], and the human limb malformation, autosomal-dominant brachydactyly type A2 (BDA2, [Dathe et al., 2009]). Several of these examples involve tissues derived mainly from mesenchymal cell types whose differentiation is directly influenced by BMP2 concentration [Wang et al., 1993; Katagiri et al., 1994; Denker et al., 1999; Sottile and Seuwen, 2000; Cheng et al., 2003; Rosen and MacDougald, 2006].

A single nucleotide polymorphism (SNP) found in an osteoporosis-linked haplotype [Styrkarsdottir et al., 2003] alters an ultraconserved sequence (83 to 446 nt downstream of the stop codon) within the *BMP2* 3'untranslated region (UTR) that has been conserved between mammals and fishes [Abrams et al., 2004]. This SNP (rs15705) was significantly associated with skeletal muscle, subcutaneous fat, and bone variation in a cohort of healthy young adults [Devaney et al., 2009]. The rs15705 SNP also altered the in vitro decay rates and specific protein affinities for RNAs bearing the ultra-conserved sequence [Fritz et al., 2006] and the expression of luciferase reporter genes [Devaney et al., 2009; Jiang et al., 2010b]. This SNP also would alter the hybridization of a microRNA (miR-568) to the BMP2 mRNA. The ultra-conserved sequence and these *trans*-regulatory factors may control BMP2 levels and thus influence embryogenesis and multifactorial diseases influenced by BMP2.

We previously used cell culture models and transgenic mice to show that the ultra-conserved sequence is a post-transcriptional regulatory switch that mediates *BMP2* down-regulation in normal lung cells and up-regulation in transformed lung cells [Jiang et al., 2010b]. We now demonstrate that the ultra-conserved sequence is an autonomously acting repressor that functions independently of promoter, coding sequence, and 3'UTR in several mesenchymal cell types in vitro and in vivo.

MATERIALS AND METHODS

CELL CULTURE AND TRANSFECTION

C3H10T¹/₂ cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, D5796 Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum and 2 mM glutamine. Cells were grown in 5% CO₂ at 37°C.

Mouse primary calvarial cells. Calvaria from 4-day-old mouse pups were digested in digestion solution (0.024 g of collagenase, 6 ml of 0.25% trypsin, 6 ml of PBS, 12 ml of DMEM) at 37°C, collected and pooled, then washed with complete medium (DMEM D6546, 10% fetal bovine serum, 1% pencillin/streptomycin, 1% L-glutamine) and cultured at 37°C in a humidified incubator supplied with 5% CO₂. After reaching confluence, 5×10^5 cells were plated into 10 cm culture dishes and used for transfection.

PLASMIDS AND TRANSFECTIONS

Cells were transfected using FuGene6 Transfection Reagent (Roche, Indianapolis, IN) following the manufacturer's protocol. Twenty-four hours (C3H10T¹/₂ cells) or 48 h (primary calvarial cells) after transfection, cells were lysed with $1 \times$ Passive Lysis Buffer (Promega, Madison, WI) and luciferase activities were measured using the Luciferase Assay System (Promega, Madison, WI) following the manufacturer's protocol.

Luciferase plasmids. RPL10-Luc (pSGG_3UTR_empty) and RPL10-Luc-3'UTR (pSGG_3UTR_BMP2, catalog #S208437) were purchased from Switch Gear Genomics (Menlo Park, CA). The BMP2 plasmid was fully sequenced, compared to the human BMP2 reference sequence NM_001200.2, and shown to bear 1,254 nt of BMP2 sequence with the full-length BMP2 3'UTR including both polyadenylation signals [Fritz et al., 2006; Liu et al., 2008]. BmpLuc (mouse nt -1,237 to 471 relative to the distal promoter, pGL1.7XX) and BmpLucUCS (mouse nt -1,237 to 471 and mouse 9,574 to 9,938 nt relative to the distal promoter or +83 to 446 relative to the stop codon, pGLB2-5'mouseCNS) were described previously [Fritz et al., 2004]. CMVLUCBmp (pC β SLucmHCNSPvAcGH) containing the mouse (9,574–9,938 nt) ultra-conserved sequences inserted downstream of luciferase in CMVLUC (pC β SLuc) was described in [Devaney et al., 2009].

BMP2 expression plasmids. CMV-BMP2-UCS (pCβs hBMP2 hCNS) was generated by replacing the luciferase gene from pCβSLuchHCNSHcAcGH containing the human ultra-conserved sequence nt 11,488 to 11,877 relative to the distal promoter [Jiang et al., 2010b] with a T4 DNA polymerase filled-in *Eco*RV and

TABLE I. PCR Primers and Predicted Amplicon Sizes

Target gene	Forward	Reverse	Amplicon (bp)
<i>Bmp2</i> , 3rd exon	CCACAAACGAGAAAAGCGTCAAGCC	CAGTAAAAGGCATGATAGCCCGGAG	146
Actb (semi-quantitative)	GGGAAATCGTGCGTGACATCAAAGAG	GCCATCATCACTTCCTGAC	359
lacZ (real time)	AGGCCACGGCGCTAATCAC	GGCGGGAAGGATCGACAGAT	61
lacZ (semi-quantitative)	CGCTGGATCAAATCTGTCGATCC	AGGTATTCGCTGGTCACTTCGATG	512
loxP spanning reporter probe	GGCGGAAAGTCCAAATTG	GCCATCATCACTTCCTGAC	1,317 (no Cre), 480 (+Cre)
βgeo coding to past SVpA	CGCCTTCTATCGCCTTCTTGACG	CCTCTACAGATGTGATATGGCTG	165
βgeo coding to past SVpA	CGCCTTCTATCGCCTTCTTGACG	CCATCACACTGGCGCTGCACG	506

*Xba*I BMP2 coding fragment from pcDNA31huBMP2 (provided by J. Patrick O'Connor, UMDNJ-NJMS). CMV-BMP2 (pCβshBMP2 GH) was made by inserting the blunted BMP2 fragment into pCβsBGHpA [Natalizio et al., 2002].

ANIMALS

All animals were handled in accordance with the Guidelines for Care and Use of Experimental Animals and approved by the NJMS IACUC (protocols #04086, #00100). The transgene construct pGLB25'3'LacZloxpCNS and the production of transgenic mice by oocyte microinjection was described previously [Fritz et al., 2006]. The β -gal expression pattern of the reporter gene in transgenic mice was detected by whole-mount X-Gal staining [Agah et al., 1997]. The mice that constitutively express Cre-recombinase under the control of the CMV promoter (CMV-Cre) were described previously [Schwenk et al., 1995].

PCR AND PRIMERS

Genomic DNA isolated from Cre-negative or Cre-positive β -gal transgene littermates was genotyped for the presence of the intact or recombined transgene by semi-quantitative PCR as follows: 95°C, 5 min; followed by 24–30 cycles of 94°C, 30 s; 57°C, 30 s; 72°C, 1.5 min; ending with a final longer extension cycle of 2 min at 94°C, 2 min at 57°C, and 10 min at 72°C. PCR primers and amplicon lengths are in Table I. Real time PCR was performed on an Applied Biosystems 7500 Real Time PCR machine with version 2.0.1 of the associated software. The ABI TaqMan probe for the mouse β -actin gene (Mm00607939_s1, ABI FAM-labeled TaqMan MGB probe) was the endogenous reference. The number of transgene copies was determined by the comparative Ct method, where $2^{-\Delta\Delta Ct}$ yields the relative copy number of β -actin or the *lacZ* bearing transgene.

Genomic DNA and total RNA was collected from the tails of the BAC transgenic weanlings using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) and an Aurum Total RNA Fatty and Fibrous Kit (BioRad, Hercules, CA), respectively. Approximately 1 μ g of total RNA was converted to cDNA using SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen, Carlsbad, CA), and an equal amount was used for a control reaction where reverse-transcriptase was omitted. The three resulting samples were then measured by quantitative PCR on a single-color iCycler (BioRad) with SYBR GreenER qPCR SuperMix for iCycler (Invitrogen). The samples were measured in triplicate and the resulting Ct values were transformed, averaged, and normalized to the values obtained from genomic DNA.

IMMUNOHISTOCHEMISTRY

Whole-mount tissues stained for β gal were embedded in paraffin and sectioned (6 mm). Sections were boiled for 20 min in 0.01 M citrate buffer for antigen retrieval, blocked with 5% donkey serum in 0.1% Tween-20/PBS, incubated with primary antibodies against α -SMA (Dako North America, Inc., Carpinteria, CA), followed by




Fig. 1. Ultra-conserved sequence (UCS) mediated repression is contextindependent in immortalized and primary mesenchymal cells. Luciferase reporter genes were driven by the ribosomal protein L10 (RPL10), Bmp2 (Bmp), or cytomegalovirus (CMV) promoter only upstream of the luciferase gene (RPL10-LUC or BmpLuc or CMVLUC). The effect of 1,254 nt of BMP2 sequence bearing the full-length 3'UTR with UCS inserted downstream of the luciferase open reading frame (RPL10-Luc-3'UTR) on luciferase activity was assessed in C3H10T1/2 pluripotent mesenchymal cells (A, n = 6). The effect of the isolated UCS (BmpLucUCS, CMVLucUCS, +83 to 446 nt relative to the Bmp2 stop codon) was assessed in primary mouse calvarial cells (B, n = 6). Relative reporter activity is shown \pm SEM. We previously demonstrated in C3H10T1/2 cells that BmpLucUCS and CMVLucUCS were 62% and 76% less active relative to the corresponding promoter-only plasmids [Devaney et al., 2009]. The Bmp2- and RPL10-driven plasmids bear the SV40 late poly(A) signal (SVpA). The RPL10-Luc-3'UTR plasmid also bears the full-length 3'UTR with the two natural Bmp2 poly(A) signals (B2pA). The CMV plasmids bear the bovine growth hormone (BGHpA) signal.

Alexa-conjugated secondary antibody (Molecular Probes/Invitrogen, Carlsbad, CA) incubation to visualize the antibody binding.

ALKALINE PHOSPHATASE STAINING

Cells were rinsed in PBS, fixed in 100% methanol for 1 min at room temperature, rinsed with PBS, then overlaid with ALP buffer (100 mM Tris-HCl, pH9; 150 mM NaCl, 1 mM MgCl₂) with freshly added 0.15 mg/ml BCIP and 0.3 mg/ml NBT (BCIP/NBT Color Development Substrate, Promega, Madison, WI).

RESULTS

ULTRA-CONSERVED SEQUENCE-MEDIATED REPRESSION IS NOT INFLUENCED BY VECTOR CONTEXT

A messenger RNA molecule can fold into numerous complex structures. The post-transcriptional regulatory proteins that control mRNA processing, nuclear export, translation efficiency, and stability recognize both primary sequence and secondary structure. Consequently, the function of any post-transcriptional regulatory element is often influenced by the flanking mRNA sequence. We previously tested the effect of the ultra-conserved sequence on vectors driven by the Bmp2 promoter (BmpLUC) or a constitutive cytomegalovirus (CMV) promoter (CMVLuc) in transiently transfected C3H10T1/2 cells. The luciferase activity of each vector was repressed by 62% and 76% respectively [Devaney et al., 2009]. We further tested if vector context altered ultra-conserved sequencemediated repression by testing the effect of a 1,254 bp fragment bearing the full-length 3'UTR in a vector driven by the ribosomal protein L10 promoter (RPL10). Like the Bmp2 and CMV-driven vectors, the RPL10 vector was significantly repressed by the 3'UTRbearing fragment (Fig. 1A, compare RPL10-Luc to RPL10-Luc-3'UTR). In addition to different promoters, these three vectors had highly distinct 3'UTRs. The RPL10 vector had the full-length Bmp2 3'UTR including the two Bmp2 poly(A) signals located 879 and 1,175 nt downstream of the *Bmp2* stop codon [Fritz et al., 2004; Liu et al., 2008] followed by an SV40 poly(A) signal. The *Bmp2*-driven vectors had the isolated ultra-conserved sequence followed by an SV40 poly(A) signal. The CMV vectors had the isolated ultra-conserved sequence followed by a bovine growth hormone poly(A) signal. The strong repression observed in all three contexts indicates that promoter, 5'UTR, and other 3'UTR elements did not influence ultra-conserved sequence-mediated repression in C3H10T¹/₂ cells.

THE ULTRA-CONSERVED SEQUENCE REPRESSES GENE EXPRESSION IN PRIMARY MESENCHYMAL CELLS

C3H10T¹/₂ mesenchymal cells have been widely studied in the contexts of BMP2-regulated myoblast, adipocyte, and osteoblast differentiation and calcification [Katagiri et al., 1990; Wang et al., 1993; Cheng et al., 2003; Shao et al., 2005; Rosen and MacDougald, 2006]. However, they are immortalized cells that may have acquired altered regulatory properties. Like C3H10T¹/₂ cells, mouse calvarial cells are mesenchymal cells that can differentiate into osteoblasts and adipose cells. Consequently, we compared the luciferase activity of primary mouse calvarial cells transfected with CMVLuc or BMPLuc to cells transfected with CMVLucUCS or BMPLucUCS. Figure 1B shows that, as in C3H10T¹/₂ cells, the ultra-conserved sequence significantly repressed luciferase expression generated from either vector in primary calvarial cells.

ULTRA-CONSERVED SEQUENCE-MEDIATED REPRESSION IN MESENCHYMAL CELLS OF THE AORTA AND CORONARY VASCULATURE IN TRANSGENIC MICE

To understand the function of the ultra-conserved sequence in vivo, we previously generated two lines of transgenic mice bearing a *lacZ* transgene driven by the mouse *Bmp2* promoter region, the entire *Bmp2* 3'UTR and 934 nt of downstream sequence [Fritz et al., 2006]. Two loxP sites were inserted flanking the ultra-conserved sequence in the reporter gene to allow its in vivo excision




Fig. 2. Cre-recombinase mediated excision of the ultra-conserved sequence in mice. Diagrams of a reporter transgene with the murine *Bmp2* promoter (nt -1,237 to 471) and 3'UTR regions (nt 9,392-11,604) flanking the *lacZ* gene. \bigtriangledown marks the *loxP* sites flanking the ultra-conserved sequence (UCS, nt 9,392-10,200). The approximate locations of the two natural *Bmp2* poly(A) signals at 10,332 and 10,619 [Fritz et al., 2004; Liu et al., 2008] relative to the promoter (yielding 3'UTRs of \sim 870 and 1,175 nt, respectively) are indicated by arrows (). Primers that flanked the *loxP* sites were used for PCR to demonstrate complete excision of the ultra-conserved sequence. DNA from two *Bmp2* transgenic littermates were amplified for 24 to 30 cycles as marked. The right series of reactions used DNA from a Cre-positive littermate. Direct sequencing and the size of the amplification products confirmed the predicted sequences of both the intact or recombined transgenes. PCR quantification and sequencing of the junctions between transgene copies indicate that three copies of the intact transgene inserted into the genome in a head to tail orientation. In +Cre mice, recombination yielded one copy of the recombined transgene at this site.

from 3'UTR by Cre-recombinase (Fig. 2). If the ultra-conserved sequence represses *Bmp2*, then deleting the ultra-conserved sequence will up-regulate the reporter gene. We mated mice with the floxed *Bmp2* reporter transgene to mice that ubiquitously express Cre-recombinase under control of the CMV promoter (CMV-Cre, [Schwenk et al., 1995]). The amplified products from the PCR reaction shown in Figure 2 demonstrates that Cre-recombinase caused complete deletion of the ultra-conserved sequence from the reporter transgene.

We stained isolated calvarial cells from transgenic mice that possessed either the intact (no Cre) reporter vector or the recombined vector (+Cre) for β gal activity. A few β gal-positive cells were observed in the +Cre plates only. However, these cells were rare and were very faintly stained (data not shown). This was expected because a potent osteoblast enhancer of *Bmp2* expression (ECR1) is located 156 kb downstream of the *Bmp2* gene [Chandler et al., 2007; Dathe et al., 2009; Jiang et al., 2010a]. As a post-transcriptional regulatory element, the function of the ultra-conserved sequence can only be detected in cells where the reporter gene is transcribed. Without the ECR1 enhancer, the low copy number transgene would be poorly transcribed in calvarial cells. The absence of an mRNA makes it impossible for this transgene to query the posttranscriptional effect of the ultra-conserved sequence.

However, the recombined transgene lacking the ultra-conserved sequence (+Cre) was strongly expressed in the coronary vasculature and aorta (Fig. 3A). The recombined *Bmp2* reporter gene was robustly expressed in all smooth muscle cells of both the ascending and descending aorta of +Cre mice. In contrast, few cells in the heart or aorta expressed the intact transgene (no Cre). Immuno-histochemical analyses using α -smooth muscle actin (SMA) established that β gal occurred in smooth muscle cells (SMC) which have a mesenchymal origin (Fig. 3B,C). Interestingly, isolated cells within the aorta (Fig. 3C) occasionally expressed the intact transgene in mice lacking Crerecombinase (no Cre). The potential significance of this apparently "leaky" expression will be discussed.

An independent transgene observation corroborates the hypothesis that the ultra-conserved sequence inhibits Bmp2 expression in coronary vascular cells at the post-transcriptional level. Like our Bmp2 transgene in +Cre mice, a bacterial artificial chromosome (BAC) Bmp2 reporter transgene [Chandler et al., 2007] was ectopically expressed in coronary vessels (Fig. 4). In this transgene, a strong SV40 polyadenylation (pA) signal is between the βgeo coding sequence and the Bmp2 3'UTR. This SV40 pA site was originally used in transgenes to block transcription of the natural 3'UTR [Mountford et al., 1994]. We used RT-PCR to directly confirm that this BAC reporter gene (Fig. 4C) and other Bmp2 reporter genes with this SV40 pA site [Jiang et al., 2010b] yield mRNAs lacking the ultraconserved sequence. Thus, Cre-lox mediated deletion (Fig. 3) or premature polyadenylation (Fig. 4) relieve gene repression mediated by the inclusion of the ultra-conserved sequence in the reporter mRNAs.

THE ULTRA-CONSERVED SEQUENCE REPRESSES BMP2 PROTEIN SYNTHESIS

We tested if the ultra-conserved sequence could repress the synthesis of BMP2 itself by inserting the human BMP2 coding sequence with or without the ultra-conserved sequence into a strong expression vector [Natalizio et al., 2002]. Non-transfected or mock

transfected C3H10T^{1/2} cells do not synthesize detectable levels of BMP2 [Jiang et al., 2007]. However, cells transfected with the vector bearing only the BMP2 coding region secreted large quantities of BMP2 into the culture media. In contrast, cells transfected with the vector bearing the BMP2 coding region and the ultra-conserved sequence secreted over 80% less BMP2 (Fig. 5A).


C3H10T^{1/2} cells differentiate into alkaline phosphatase-positive osteoblasts in response to BMP2 [Katagiri et al., 1990]. The BMP2 secreted in plates transfected with either the promoter-only plasmid (CMV-BMP2) or the plasmid bearing the ultra-conserved sequence (CMV-BMP2-UCS) was fully functional as assessed by the presence of alkaline phosphatase positive nodules. However, consistent with the lower level of secreted BMP2, plates transfected with the vector that included the ultra-conserved sequence developed fewer nodules (Fig. 5).


DISCUSSION


The ability of the 3'UTR to interact with *trans*-regulatory factors is a nimble and versatile mechanism for modulating the synthesis of a potent morphogen in different cell types. We have shown that the *Bmp2* ultra-conserved sequence represses gene expression in C3H10T¹/₂ mesenchymal cells and primary mouse calvarial cells (Fig. 1), and vascular smooth muscle cells (Fig. 3). Thus, these cells share a common post-transcriptional *Bmp2* regulatory mechanism. Because the concentration of BMP2 controls the differentiation programs of these pluripotent mesenchymal cells in vitro and in vivo [Katagiri et al., 1990; Vattikuti and Towler, 2004; Hruska et al., 2005; Lincoln et al., 2006; Shao et al., 2006; Srivastava, 2006], this regulatory mechanism is a potent influence on their function and behavior (Fig. 5).


The ultra-conserved sequence functions independently of promoter context, because it repressed transiently transfected luciferase genes driven by three different promoters (Bmp2, RPL10, CMV; Fig. 1). The ultra-conserved sequence functions independently of 3'UTR context, because it repressed either as an isolated element (Figs. 1 and 5) or within the intact Bmp2 3'UTR (Figs. 1 and 3). Additionally, the ultra-conserved sequence repressed reporter genes bearing three different poly(A) signals (endogenous Bmp2, bovine growth hormone (bGH), and SV40; Figs. 1 and 3). The ultra-conserved sequence in repressed inter-conserved sequence (Fig. 1), β galactosidase (Fig. 3), and BMP2 itself (Fig. 5).

The strongly autonomous function of the *Bmp2* ultra-conserved sequence may have a practical benefit. Understanding the function of BMP2 and other important proteins requires reliable strategies to alter protein levels. However, the expression of randomly inserted transgenes often fails to correlate with the number of inserted copies owing to position effects at the integration site The Smithies group developed a method to alter transgene expression by modifying the 3'UTR of the transgenes [Kakoki et al., 2004]. This post-transcriptional approach avoids chromosomal influences on transcription and successfully modulated gene expression by 100-fold. However, although two RNA elements functioned out of context, others did not. For example, two well-characterized stabilizing elements (the β globin C-rich stabilizing element












Fig. 5. The ultra-conserved sequence (UCS) represses a vector encoding functional BMP2 protein. A: C3H10T¹/₂ cells were transfected with plasmids bearing the human *BMP2* coding region with (CMV-BMP2-UCS) or without (CMV-BMP2) the UCS in the CMV-driven vector described in Figure 1. The amount of BMP2 protein in media conditioned for 2 or 5 days after transfection was measured by ELISA (R&D Systems). The average BMP2 concentration relative to the CMV-BMP2 vector is shown \pm SEM. Day 2, n = 2; day 5, n = 6. No BMP2 was detected in untreated or mock-transfected cells or in cells transfected with the empty vector. Cells were then grown for 14 days, stained for alkaline phosphatase positive nodules, and lightly stained with eosin. The graph shows the average number of nodules per square centimeter \pm SEM. No nodules were detected in cells transfected with the empty vector. B: Representative plates showing stained C3H10T¹/₂ cells transfected with the empty expression plasmid or plasmids bearing the human *BMP2* coding region with or without the UCS as described in (A).

and a part of the bovine growth hormone 3'UTR) failed to increase expression [Kakoki et al., 2004]. Our data indicates that the ultraconserved sequence is an autonomously functioning 3'UTR element that can modulate the level of BMP2 and other proteins while retaining tissue specific regulatory elements. Conditional removal of this regulatory block in specific tissues, for example by Cre-mediated excision in transgenic mice, would be a valuable and unique addition to the transgenic tool kit.

Manipulation of the *Bmp2* ultra-conserved sequence in mice and in cultured cells revealed that the *Bmp2* gene is active in many more cells than actually synthesize protein. The establishment of an initial broad field of gene expression followed by spatial restriction of protein synthesis is a common theme in embryogenesis. We occasionally observed isolated blue nuclei in the aorta of adult animals lacking the Cre gene (Fig. 3C). This suggests that these cells are poised to express *Bmp2*, but that BMP2 synthesis is post-transcriptionally repressed. Local stimuli such as inflammation or oxidative stress may relieve this repression. The retention of a mechanism whereby the *Bmp2* gene is broadly active, but synthesis is post-transcriptionally blocked has ramifications to pathological calcification in humans.

BMP2 may stimulate three clinically important forms of calcium deposition: cardiac valve, medial artery, and atherosclerotic/fibrotic

calcification [Bostrom et al., 1993; Mohler et al., 2001; Shao et al., 2005; Caira et al., 2006]. Our transgenic and tissue culture data suggest that, normally, *Bmp2* is repressed post-transcriptionally in vascular mesenchymal cells. Pathological impairment of this repression by proinflammatory signals, oxidative stress, metabolic changes, and mechanical stresses may contribute to aberrant BMP2 synthesis in calcifying tissues.

Blocking synthesis at a late step enables a nimble and versatile response to local developmental signals. In an embryo, this is particularly relevant for multi-potential mesenchymal cells that have varied embryonic origins. Furthermore, retention of this post-transcriptional block in the adult aorta and coronary vessels explains the propensity of these tissues to reinitiate BMP2 synthesis leading to pathological calcification. Understanding the molecules that sustain or release this braking mechanism is relevant to pathologies involving mesenchymal cells and abnormal BMP2 production.

ACKNOWLEDGMENTS

This work was supported by the Molecular Resource Facility at the UMDNJ-NJ Medical School (to M.B.R.), the Foundation of UMDNJ (to M.B.R.), the National Institute of Health (R01HD31117 to M.B.R.,

R21HL084278 to V.G., R01HD47880 to D.P.M.), the American Heart Association (00655881T to M.B.R., 555840T to V.G., and 0625861T to B.P.T.K.), and the March of Dimes Birth Defects Foundation (1-FY06-375 to V.G.).

REFERENCES

Abrams KL, Xu J, Nativelle-Serpentini C, Dabirshahsahebi S, Rogers MB. 2004. An evolutionary and molecular analysis of Bmp2 expression. J Biol Chem 279:15916–15928.

Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA, Schneider MD. 1997. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J Clin Invest 100:169–179.

Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. 2007. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 27:2589–2596.

Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. 1993. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91:1800–1809.

Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. 2006. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47:1707–1712.

Castranio T, Mishina Y. 2009. Bmp2 is required for cephalic neural tube closure in the mouse. Dev Dyn 238:110–122.

Chandler RL, Chandler KJ, McFarland KA, Mortlock DP. 2007. Bmp2 transcription in osteoblast progenitors is regulated by a distant 3' enhancer located 156.3 kilobases from the promoter. Mol Cell Biol 27:2934–2951.

Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. 2003. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 278:45969–45977.

Choi JY, Shin CS, Hong YC, Kang D. 2006. Single-nucleotide polymorphisms and haplotypes of bone morphogenetic protein genes and peripheral bone mineral density in young Korean men and women. Calcif Tissue Int 78:203–211.

Cola C, Almeida M, Li D, Romeo F, Mehta JL. 2004. Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun 320:424–427.

Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. 2005. Regulation of bone morphogenetic protein-2 expression in endothelial cells: Role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H202, and high intravascular pressure. Circulation 111:2364–2372.

Csiszar A, Ahmad M, Smith KE, Labinskyy N, Gao Q, Kaley G, Edwards JG, Wolin MS, Ungvari Z. 2006. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol 168:629–638.

Dathe K, Kjaer KW, Brehm A, Meinecke P, Nurnberg P, Neto JC, Brunoni D, Tommerup N, Ott CE, Klopocki E, Seemann P, Mundlos S. 2009. Duplications involving a conserved regulatory element downstream of BMP2 are associated with brachydactyly type A2. Am J Hum Genet 84:483–492.

Denker AE, Haas AR, Nicoll SB, Tuan RS. 1999. Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells. I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures. Differentiation 64:67–76.

Devaney JM, Tosi LL, Fritz DT, Gordish-Dressman HA, Jiang S, Orkunoglu-Suer FE, Gordon AH, Harmon BT, Thompson PD, Clarkson PM, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Brandoli C, Hoffman EP, Rogers MB. 2009. Differences in fat and muscle mass associated with a functional human polymorphism in a post-transcriptional BMP2 gene regulatory element. J Cell Biochem 107:1073–1082. Fritz DT, Liu D, Xu J, Jiang S, Rogers MB. 2004. Conservation of Bmp2 post-transcriptional regulatory mechanisms. J Biol Chem 279:48950–48958.

Fritz DT, Jiang S, Xu J, Rogers MB. 2006. A polymorphism in a conserved posttranscriptional regulatory motif alters bone morphogenetic protein 2 (BMP2) RNA:protein interactions. Mol Endocrinol 20:1574–1586.

Hruska KA, Mathew S, Saab G. 2005. Bone morphogenetic proteins in vascular calcification. Circ Res 97:105–114.

Jiang S, Zhang S, Langenfeld J, Lo SC, Rogers MB. 2007. Mycoplasma infection transforms normal lung cells and induces bone morphogenetic protein 2 expression by post-transcriptional mechanisms. J Cell Biochem 104:580–594.

Jiang S, Chandler RL, Fritz DT, Mortlock DP, Rogers MB. 2010a. Repressive BMP2 gene regulatory elements near the BMP2 promoter. Biochem Biophys Res Commun 392:124–128.

Jiang S, Fritz DT, Rogers MB. 2010b. A conserved post-transcriptional BMP2 switch in lung cells. J Cell Biochem 110:509–521.

Kakoki M, Tsai YS, Kim HS, Hatada S, Ciavatta DJ, Takahashi N, Arnold LW, Maeda N, Smithies O. 2004. Altering the expression in mice of genes by modifying their 3' regions. Dev Cell 6:597–606.

Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM, Rosen V, Wang EA, Tanaka H, Omura S, Suda T. 1990. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 172:295–299.

Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T. 1994. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127:1755–1766.

Kruithof BP, van Wijk B, Somi S, Kruithof-de Julio M, Perez Pomares JM, Weesie F, Wessels A, Moorman AF, van den Hoff MJ. 2006. BMP and FGF regulate the differentiation of multipotential pericardial mesoderm into the myocardial or epicardial lineage. Dev Biol 295:507–522.

Lincoln J, Lange AW, Yutzey KE. 2006. Hearts and bones: Shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol 294:292–302.

Liu D, Fritz DT, Rogers MB, Shatkin AJ. 2008. Species-specific cis-regulatory elements in the 3'UTR direct alternative polyadenylation of bone morphogenetic protein 2 mRNA. J Biol Chem 283:28010–28019.

Ma L, Lu MF, Schwartz RJ, Martin JF. 2005. Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. Development 132:5601–5611.

McGuigan FE, Larzenius E, Callreus M, Gerdhem P, Luthman H, Akesson K. 2007. Variation in the BMP2 gene: Bone mineral density and ultrasound in young adult and elderly women. Calcif Tissue Int 81:254–262.

Milet J, Dehais V, Bourgain C, Jouanolle AM, Mosser A, Perrin M, Morcet J, Brissot P, David V, Deugnier Y, Mosser J. 2007. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet 81:799–807.

Milet J, Le Gac G, Scotet V, Gourlaouen I, Theze C, Mosser J, Bourgain C, Deugnier Y, Ferec C. 2010. A common SNP near BMP2 is associated with severity of the iron burden in HFE p.C282Y homozygous patients: A follow-up study. Blood Cells Mol Dis 44:34–37.

Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. 2001. Bone formation and inflammation in cardiac valves. Circulation 103: 1522–1528.

Mountford P, Zevnik B, Duwel A, Nichols J, Li M, Dani C, Robertson M, Chambers I, Smith A. 1994. Dicistronic targeting constructs: Reporters and modifiers of mammalian gene expression. Proc Natl Acad Sci USA 91:4303–4307.

Natalizio BJ, Muniz LC, Arhin GK, Wilusz J, Lutz CS. 2002. Upstream elements present in the 3'-untranslated region of collagen genes influence the processing efficiency of overlapping polyadenylation signals. J Biol Chem 277:42733–42740.

Nett PC, Ortmann J, Celeiro J, Haas E, Hofmann-Lehmann R, Tornillo L, Terraciano LM, Barton M. 2006. Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus. Life Sci 78:2213–2218.

Reneland RH, Mah S, Kammerer S, Hoyal CR, Marnellos G, Wilson SG, Sambrook PN, Spector TD, Nelson MR, Braun A. 2005. Association between a variation in the phosphodiesterase 4D gene and bone mineral density. BMC Med Genet 6:9.

Rivera-Feliciano J, Tabin CJ. 2006. Bmp2 instructs cardiac progenitors to form the heart-valve-inducing field. Dev Biol 295:580–588.

Rosen ED, MacDougald OA. 2006. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7:885–896.

Schlange T, Andree B, Arnold HH, Brand T. 2000. BMP2 is required for early heart development during a distinct time period. Mech Dev 91:259–270.

Schlueter J, Manner J, Brand T. 2006. BMP is an important regulator of proepicardial identity in the chick embryo. Dev Biol 295:546–558.

Schultheiss TM, Burch JB, Lassar AB. 1997. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev 11:451–462.

Schwenk F, Baron U, Rajewsky K. 1995. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23:5080–5081.

Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. 2005. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115:1210–1220.

Shao JS, Cai J, Towler DA. 2006. Molecular mechanisms of vascular calcification: Lessons learned from the aorta. Arterioscler Thromb Vasc Biol 26:1423–1430.

Singh AP, Castranio T, Scott G, Guo D, Harris MA, Ray M, Harris SE, Mishina Y. 2008. Influences of reduced expression of maternal bone morphogenetic protein 2 on mouse embryonic development. Sex Dev 2: 134–141.

Sottile V, Seuwen K. 2000. Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone). FEBS Lett 475:201–204. Srivastava D. 2006. Making or breaking the heart: From lineage determination to morphogenesis. Cell 126:1037–1048.

Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K. 2003. Linkage of Osteoporosis to Chromosome 20p12 and Association to BMP2. PLoS Biol 1:E69.

Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. 1998. Dietinduced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 273: 30427–30434.

Tranah GJ, Taylor BC, Lui LY, Zmuda JM, Cauley JA, Ensrud KE, Hillier TA, Hochberg MC, Li J, Rhees BK, Erlich HA, Sternlicht MD, Peltz G, Cummings SR. 2008. Genetic variation in candidate osteoporosis genes, bone mineral density, and fracture risk: The study of osteoporotic fractures. Calcif Tissue Int 83:155–166.

Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V. 2006. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38: 1424–1429.

Uchimura T, Komatsu Y, Tanaka M, McCann KL, Mishina Y. 2009. Bmp2 and Bmp4 genetically interact to support multiple aspects of mouse development including functional heart development. Genesis 47:374–384.

Valdes AM, Hart DJ, Jones KA, Surdulescu G, Swarbrick P, Doyle DV, Schafer AJ, Spector TD. 2004. Association study of candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum 50:2497–2507.

Valdes AM, Van Oene M, Hart DJ, Surdulescu GL, Loughlin J, Doherty M, Spector TD. 2006. Reproducible genetic associations between candidate genes and clinical knee osteoarthritis in men and women. Arthritis Rheum 54:533–539.

Vattikuti R, Towler DA. 2004. Osteogenic regulation of vascular calcification: An early perspective. Am J Physiol Endocrinol Metab 286:E686–E696.

Wang EA, Israel DI, Kelly S, Luxenberg DP. 1993. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9:57–71.

Zhang H, Bradley A. 1996. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 122: 2977–2986.